Objective: to evaluate the effect of combined medication (human immunoglobulin+Yinzhihuang) in the treatment of neonatal ABO hemolytic jaundice. Methods: 100 newborns with ABO hemolytic jaundice treated in xian county...Objective: to evaluate the effect of combined medication (human immunoglobulin+Yinzhihuang) in the treatment of neonatal ABO hemolytic jaundice. Methods: 100 newborns with ABO hemolytic jaundice treated in xian county Hospital of Traditional Chinese Medicine from January 2020 to June 2022 were randomly divided into two groups. For the 50 children in the control group, only human immunoglobulin was used, while for the 50 children in the observation group, human immunoglobulin and Yinzhihuang were used. The treatment effect, symptom improvement, before and after treatment between groups were analyzed. Results: the total effective rate of the observation group was 96.00%, which was significantly higher than that of the control group (84.00%, P < 0.05). In the observation group, the time for jaundice to subside, the time for first defecation, and the time for stool to turn yellow were all shorter than those in the control group, and the daily defecation times were more than those in the control group (P < 0.05). Before treatment, there was no difference in total bilirubin (TBIL), direct bilirubin (DBIL) and indirect bilirubin (IBIL) levels between the two groups (P > 0.05). After treatment, the levels of TBIL, DBIL and IBIL in the observation group were lower than those in the control group (P < 0.05). Before treatment, there was no difference in the levels of superoxide dismutase (SOD), malondialdehyde (MDA), CD4 and CD8 between the two groups (P > 0.05). After treatment, the levels of SOD, CD4 and CD8 in the observation group were higher than those in the control group, while the level of MDA was lower than that in the control group (P < 0.05). Before treatment, there was no difference between the two groups in behavioral ability, passive muscle tone, active muscle tone, original reflex and general evaluation (P > 0.05). After treatment, the scores of NBNA scale in the observation group were higher than those in the control group (P < 0.05). Conclusion: in the treatment of neonatal ABO hemolytic jaundice, the combination of human immunoglobulin and Yinzhihuang can achieve ideal results, and can better improve the serum bilirubin level, biochemical index level and neurobehavioral score, which is worthy of reference and application.展开更多
文摘Objective: to evaluate the effect of combined medication (human immunoglobulin+Yinzhihuang) in the treatment of neonatal ABO hemolytic jaundice. Methods: 100 newborns with ABO hemolytic jaundice treated in xian county Hospital of Traditional Chinese Medicine from January 2020 to June 2022 were randomly divided into two groups. For the 50 children in the control group, only human immunoglobulin was used, while for the 50 children in the observation group, human immunoglobulin and Yinzhihuang were used. The treatment effect, symptom improvement, before and after treatment between groups were analyzed. Results: the total effective rate of the observation group was 96.00%, which was significantly higher than that of the control group (84.00%, P < 0.05). In the observation group, the time for jaundice to subside, the time for first defecation, and the time for stool to turn yellow were all shorter than those in the control group, and the daily defecation times were more than those in the control group (P < 0.05). Before treatment, there was no difference in total bilirubin (TBIL), direct bilirubin (DBIL) and indirect bilirubin (IBIL) levels between the two groups (P > 0.05). After treatment, the levels of TBIL, DBIL and IBIL in the observation group were lower than those in the control group (P < 0.05). Before treatment, there was no difference in the levels of superoxide dismutase (SOD), malondialdehyde (MDA), CD4 and CD8 between the two groups (P > 0.05). After treatment, the levels of SOD, CD4 and CD8 in the observation group were higher than those in the control group, while the level of MDA was lower than that in the control group (P < 0.05). Before treatment, there was no difference between the two groups in behavioral ability, passive muscle tone, active muscle tone, original reflex and general evaluation (P > 0.05). After treatment, the scores of NBNA scale in the observation group were higher than those in the control group (P < 0.05). Conclusion: in the treatment of neonatal ABO hemolytic jaundice, the combination of human immunoglobulin and Yinzhihuang can achieve ideal results, and can better improve the serum bilirubin level, biochemical index level and neurobehavioral score, which is worthy of reference and application.
